Table 1.
Samples | Total Reads |
Processed Reads |
Q20 (%) | Q30 (%) | GC (%) | Mapped Reads |
Unmapped Reads |
---|---|---|---|---|---|---|---|
UTZF-1 | 72,783,012 | 71,783,716 | 98.91 | 96.05 | 43.62 | 60,458,452 (84.22%) |
11,325,264 (15.78%) |
UTZF-2 | 61,925,392 | 60,857,682 | 98.91 | 96.06 | 44.95 | 51,896,692 (85.28%) |
8,960,990 (14.72%) |
UTZF-3 | 60,878,020 | 59,726,314 | 98.85 | 95.87 | 46.00 | 51,603,485 (86.40%) |
8,122,829 (13.60%) |
ETZF-1 | 88,823,364 | 87,431,000 | 99.06 | 96.55 | 50.43 | 70,539,606 (80.68%) |
16,891,394 (19.32%) |
ETZF-2 | 67,022,082 | 65,997,010 | 99.88 | 96.00 | 46.40 | 55,889,349 (84.68%) |
10,107,661 (15.32%) |
ETZF-3 | 66,550,392 | 65,065,792 | 98.97 | 96.27 | 47.32 | 55,066,792 (84.10%) |
10,414,184 (15.90) |
UTZF, untreated zebrafish; ETZF, etridiazole-treated zebrafish; Q20 (%), percentage of Phred quality score 20 percentage; Q30 (%), percentage of Phred quality score 30; GC (%), percentage of guanine–cytosine.